Eli Lilly and Company (NEO: LLY)

Market Cap	1.03T
Revenue (ttm)	55.20B
Net Income (ttm)	11.31B
Shares Out	n/a
EPS (ttm)	12.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,554
Open	31.00
Previous Close	31.04
Day's Range	30.53 - 31.03
52-Week Range	20.91 - 36.42
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 43,000
• Stock Exchange: Cboe Canada
• Ticker Symbol: LLY

Financial Performance

In 2023, Eli Lilly and Company's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.

Financial numbers in USD